Business

Where are we going? Where have we been? What is the future? Last month, Tempus purchased Paige AI for $81M, largely in the form of Tempus stock to, as reports mention, for PaigeAI's datasets from 7 million slides, perhaps most of...

From the Proscia blog: For HNL Lab Medicine, digital pathology isn’t just a technology upgrade—it’s a strategic business decision that has already delivered measurable gains. By partnering with Proscia, HNL Lab Medicine has not only...

Cancer patients will benefit from the potential for faster diagnosis and better access to specialist opinions, following the go-live of a digital pathology solution across five NHS sites in Devon and Cornwall.  Technical and...

Tempus: Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a...

Lumea, the U.S. leader in primary clinical digital pathology, is proud to announce it has received four prestigious awards this fall, recognizing the company's rapid growth and transformative impact on cancer diagnostics. Lumea was named to the...

OREM, Utah--(BUSINESS WIRE)--Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion™ (research use only (RUO) in the US, CE-IVDD-marked in...